T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
CRISPR Therapeutics
CRSP
$5.22B
| $34.8M | ﹤0.01% |
738,869
+121,176
| +20% | +$4.84M |
|
1002
Addus HomeCare
ADUS
$2.2B
| $34.6M | ﹤0.01% |
461,971
-305
| -0.1% | -$21.1K |
|
|
PLAN
1003
DELISTED
Anaplan, Inc.
PLAN
| $34.5M | ﹤0.01% |
684,177
-59,813
| -8% | -$2.47M |
|
1004
Ziff Davis
ZD
$1.88B
| $34.5M | ﹤0.01% |
446,159
+3,915
| +0.9% | +$296K |
|
1005
REX American Resources
REX
$1.44B
| $34.4M | ﹤0.01% |
2,830,980
-25,482
| -0.9% | -$334K |
|
1006
Resideo Technologies
REZI
$3.89B
| $34.4M | ﹤0.01% |
1,568,130
+46,423
| +3% | +$981K |
|
1007
Angi Inc
ANGI
$176M
| $34.3M | ﹤0.01% |
263,874
-285,897
| -52% | -$44.1M |
|
1008
Ameren
AEE
$30.1B
| $34.1M | ﹤0.01% |
453,775
+1,985
| +0.4% | +$146K |
|
1009
Regenxbio
RGNX
$720M
| $34M | ﹤0.01% |
661,299
-59,505
| -8% | -$2.97M |
|
1010
RenaissanceRe
RNR
$13.2B
| $33.8M | ﹤0.01% |
189,984
-23,219
| -11% | -$3.82M |
|
1011
Chipotle Mexican Grill
CMG
$41.3B
| $33.7M | ﹤0.01% |
2,298,450
-3,150
| -0.1% | -$44.4K |
|
1012
Amcor
AMCR
$21.5B
| $33.7M | ﹤0.01% |
+585,784
| New | +$32.5M |
|
1013
Huntington Ingalls Industries
HII
$12.9B
| $33.6M | ﹤0.01% |
149,333
-2,186
| -1% | -$469K |
|
1014
Commault Systems
CVLT
$5.87B
| $33.5M | ﹤0.01% |
675,029
-1,215
| -0.2% | -$64.6K |
|
1015
Universal Logistics Holdings
ULH
$518M
| $33.3M | ﹤0.01% |
1,483,480
-14,512
| -1% | -$310K |
|
1016
Globus Medical
GMED
$11.5B
| $33.3M | ﹤0.01% |
787,000
-388
| -0% | -$16.8K |
|
1017
Brunswick
BC
$5.21B
| $33.1M | ﹤0.01% |
721,749
-284
| -0% | -$13.7K |
|
|
NEX
1018
DELISTED
NexTier Oilfield Solutions Inc.
NEX
| $32.9M | ﹤0.01% |
4,901,787
-58,448
| -1% | -$546K |
|
1019
ResMed
RMD
$32.8B
| $32.7M | ﹤0.01% |
268,369
+1,718
| +0.6% | +$190K |
|
1020
CBRE Group
CBRE
$42.7B
| $32.2M | ﹤0.01% |
628,423
-2,071
| -0.3% | -$103K |
|
1021
Employers Holdings
EIG
$864M
| $32.2M | ﹤0.01% |
762,026
-13,313
| -2% | -$557K |
|
|
LL
1022
DELISTED
LL Flooring Holdings, Inc.
LL
| $32.1M | ﹤0.01% |
2,776,280
+21,488
| +0.8% | +$242K |
|
1023
Blue Bird Corp
BLBD
$2.04B
| $32M | ﹤0.01% |
1,627,399
-14,636
| -0.9% | -$268K |
|
|
DRE
1024
DELISTED
Duke Realty Corp.
DRE
| $32M | ﹤0.01% |
1,013,312
-1,171,279
| -54% | -$36.2M |
|
1025
Leidos
LDOS
$17.6B
| $31.6M | ﹤0.01% |
395,815
+73,767
| +23% | +$5.39M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.